Rathbones Group PLC Medicenna Therapeutics Corp. Transaction History

Rathbones Group PLC

  • $19 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 03, 2022
BUY
$0.83 - $1.78 $54,500 - $116,880
65,663 Added 164.16%
105,663 $87,000
Q3 2020

Nov 13, 2020
BUY
$3.55 - $4.67 $142,000 - $186,800
40,000 New
40,000 $164,000

About Medicenna Therapeutics Corp.

MDNA Quotes by TradingView
  • Ticker MDNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,637,504
  • Market Cap $21.6M
  • Description
  • Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as...
More about MDNA
Track This Portfolio

Track Rathbones Group PLC Portfolio

Follow Rathbones Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rathbones Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Rathbones Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email